Actively Recruiting
Development and Validation of Non-Invasive Eye-Tracking Biomarkers to Monitor Cognitive Changes in Alzheimers Disease
Led by McGill University · Updated on 2026-10-14
250
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are developing and validating a sensitive, non-invasive eye-tracking software application to study Alzheimers Disease and related cognitive changes. This study involves participants with Alzheimers Disease and healthy controls to evaluate cognitive functions affected by the disease using brief cognitive tests and eye movement measurements. The goal is to create machine learning algorithms that track disease progression and cognitive decline. Participants will undergo eye-tracking tests using an electronic tablet and its embedded camera to capture eye movements in response to visual stimuli. The study includes two groups 125 Alzheimers patients and 125 healthy individuals without neurodegenerative disorders. Data collected will help validate the software application designed to monitor Alzheimers progression. During the study, participants will complete brief cognitive tests including the Clinical Dementia Rating, Montreal Cognitive Assessment, and Mini-Mental State Exam at enrollment. Eye movement data will be recorded non-invasively with the tablet. Researchers will analyze these measures to understand cognitive changes associated with Alzheimers. The total participation duration varies, with assessments occurring primarily at enrollment.
CONDITIONS
Brief Title
Development of Eye-movement Based Biomarkers in Alzheimer's Disease
Research Team
L
Luciano Buonamici
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here